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Available online 2 January 2016Objectives. Aberrant expressions of LIN-28B, let-7a and IGF-II occur in epithelial ovarian cancer, and the
LIN-28B/let-7a/IGF-II axis is associated with human disease. The purpose of this study was to investigate the as-
sociations between LIN-28B/let-7a/IGF-II axis molecular subtypes and epithelial ovarian cancer prognosis.
Methods. Using quantitative reverse transcription PCR, we analyzed LIN-28B, let-7a and IGF-IImRNA in 211
primary epithelial ovarian cancer tissues, and also performed Classification and Regression Tree (CART) and sur-
vival analyses.
Results. Four terminal subtypes were identified in the CART analysis in combination with survival analysis.
Kaplan–Meier survival curves showed that subtypes LIN-28Blowlet-7alow and LIN-28Blowlet-7ahigh IGF-IIlow had
significantly better survival than subtypes LIN-28Bhigh or LIN-28Blow let-7ahigh IGF-II high (p b 0.0001 for overall,
p = 0.017 for progression-free survival, respectively). Multivariate Cox regression models showed that
compared to subtype LIN-28Bhigh, subtypes LIN-28Blowlet-7alow and LIN-28Blowlet-7ahighIGF-IIlow had significantly
reducedmortality and reduced relapse risks. Moreover, subtype LIN-28Blow let-7alow had better response to che-
motherapy than subtype LIN-28Bhigh.
Conclusions. These results suggest that molecular subtypes of the LIN-28B/let-7a/IGF-II axis associate with
heterogeneous progression and may have clinical implications in predicting epithelial ovarian cancer prognosis.
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LIN-28B, a paralog of LIN-28A, is a cancer stem cell-associated tran-
scription factor, and plays an important role in maintaining stem cell-
like properties and tumorigenicity [1,2]. LIN-28B was first identified in
human liver cancer [2], and shares 77% identity in protein sequence
with LIN-28A. It contains a cold-shock domain (CSD) and two
retroviral-type CCHC zinc finger domains (ZFMs) [3,4]. A negative feed-
back regulatory loop exists between LIN-28B and miRNA let-7a. With
RNA-binding domains, LIN-28B is able to affect the biogenesis of
miRNA let-7members with a slightly stronger effect on let-7a, reducing
let-7a maturation and its abundance by sequestering primary let-7a
(pri-let-7a) in the nucleus [3,5], and thereby activating its many onco-
gene targets including k-RAS, c-MYC, HMGA2, cyclin D1, insulin-like
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through the complementary binding sites of let-7a to the 3′-UTRs
[5–7]. Conversely, miRNA let-7a can also, in turn, control the expression
of LIN-28B [2], and indirectly affects the stability of LIN-28B protein via
the ubiquitin ligase TRIM71 via let-7a binding sites in its 3′-UTR [8]. In-
hibition of LIN-28B promotes thematuration of let-7, thereby leading to
the translation reduction of let-7a targets such as c-MYC and RAS, and
the decreased tumorigenesis [9]. In addition, the critical role of LIN-
28B/let-7 axis has been demonstrated in programing and maintaining
stem cells [10,11], aswell as in promoting epithelial-mesenchymal tran-
sition (EMT) [12], tumorigenesis and metastasis [11]. The involvement
of the LIN-28B/let-7 axis in cancer has also been studied in vivo neuro-
blastoma animalmodel; LIN-28B overexpression-induced neuroblastma
had markedly low levels of let-7miRNA and high levels of MYC protein
[13]. Frequent dysregulation of LIN-28B in human cancers including
liver, breast, and ovary suggests that LIN-28B functions as an oncogene
[2,6,11,14,15], influencing disease prognosis and patient response to
treatment [5].
Mitogenic growth factor IGF-II together with its receptor IGF-IR
plays an important role in carcinogenesis and tumor progression. The
association of IGF-II overexpression and increased risk of human cancer
including ovarian cancer, and poor cancer survival has been reported
previously [16,17]. Animal models and in vitro experiments show that
IGF-IR inhibition can increase the efficacy of chemotherapy and sup-
press tumor-cell growth [18], suggesting that the suppression of IGF-
II/IGF-IR may benefit patients with malignancies. Besides loss of im-
printing (LOI) and promoter methylation, LIN-28A/LIN-28B and
miRNA let-7a also contribute to the regulation of IGF-II expression [7,
19,20]. Elevated let-7a expression has been positively associated with
increased expression of IGF-II [7,20]. In addition to its ability to suppress
let-7amaturation, LIN-28B is also involved in regulating mRNA targets,
such as IGF-II, HMGA1, OCT4, and cyclins via let-7a-independent mecha-
nisms [21]. A positive correlation has been observed between the ex-
pressions of LIN-28B and IGF-II in cancer tissues [5]. It has been
reported that the LIN-28B/IGF-II axis is linked to the progression of
head and neck cancer [22]. Furthermore, Kallen and colleagues recently
showed that miRNA let-7a activity can be antagonized by long non-
coding RNA H19 [23], which is regulated with its neighboring IGF-II
gene through a reciprocal DNA methylation-dependent mechanism in
the imprinting control region. Through the direct or indirect regulation
network, RNA protein LIN-28B,miRNA let-7a and the growth factor IGF-
II form an axis, which in different combinationsmay drive differences in
phenotypes of human diseases including human cancer, given that each
component of the axis has been shown in association with develop-
ment, cell proliferation and apoptosis [1,2,6,7,24]. We asked whether
ovarian cancer patients with heterogeneous phenotypes had different
molecular subtypes of the axis. Thus, we evaluated the associations be-
tween the LIN-28B/let-7a/IGF-II axis molecular subtypes and both the
clinicopathologic characteristics and survival of patients with epithelial
ovarian cancer.
2. Materials and methods
2.1. Patients and tumor samples
With the approval of the ethics review committee and signed in-
formed consent of patients, fresh tumor samples were collected
from 211 epithelial ovarian cancer patients when they received
cytoreduction surgery for primary ovarian cancer in the Department
of Gynecology and Obstetrics at the University of Turin between
October 1991 and February 2000. The specimens were snap-frozen
in liquid nitrogen immediately after resection, and then transferred
to a −80 °C freezer for storage. Clinical and pathology information
on these patients was retrieved from their medical charts and pa-
thology reports. Disease stage, tumor grade and histology were de-
termined based on the International Federation of Gynecology andObstetrics (FIGO) classification and the WHO guidelines [25,26].
Most of the patients (n = 178) received standard post-operative
platinum-based chemotherapy after cytoreduction surgery. For pa-
tients treated between 1991 and 1995, cisplatin (75 mg/m2) and cy-
clophosphamide (750 mg/m2) were administered every 3 weeks for
6 cycles as the standard of care except for patients who had allergic
reactions or medical contraindications. From 1996, when paclitaxel
was introduced as standard of care, patients were treated with pac-
litaxel (175 mg/m2, 3 h infusion) and carboplatin at an area under
the concentration time curve of 5 or 6, every 3 weeks for 6 cycles. Pa-
tient response to chemotherapy was evaluated 1 month after the
last cycle of treatment through clinical examination, imaging and
serum CA-125. Pathologic evaluation by second-look laparotomy
was performed for some patients following the institutional proto-
cols at the time. Patients were subsequently followed through June
2001 for disease progression. The median follow-up time was
31 months with a range from 0.6 to 114 months.
“Measurable disease” was determined following the WHO
criteria [27]. Four categories of patient response to chemotherapy
were defined in this study, including (a) complete response: resolu-
tion of all evidence of the disease for at least one month, (b) partial
response: a decrease of ≥50% in the product of the diameters (maxi-
mum and minimum) of all measurable lesions without the develop-
ment of new lesions for at least one month, (c) stable disease: a
decrease of b50% or an increase of b25% in the product of the diam-
eters of all measurable lesion, and (d) progressive disease: an in-
crease of ≥25% in the product of the diameters of all measurable
lesions or the development of new lesions. For non-measurable dis-
ease, progression was defined as the doubling of CA-125 from the
upper limit of normal [28]. Of 178 patients receiving chemotherapy,
176 had available information on chemotherapy response; 128
(72.7%) who had complete response were classified as ‘Yes’ to treat-
ment response, while 48 (27.3%) whowere in the other three catego-
ries were grouped as ‘No’ response, which included 36 with partial
response, 4 with stable disease, and 8 with progressive disease.
2.2. Total RNA extraction and analysis of lin-28B, let-7a and IGF-II
expressions
Frozen tumor specimens, which had been examined by two inde-
pendent pathologists to confirm that each specimen contained greater
than 80% tumor cells, were pulverized manually in liquid nitrogen,
and approximately 100 mg samples of tissue powder were used for ex-
traction of total RNA through a standard phenol-chloroform approach.
The quality of RNase-free DNase-treated total RNA was determined
after 1% agarose gel electrophoresis for the integrity of 18s and 28s
rRNA, and the quantity of the extracted RNA samples was determined
by spectrophotometer.
Cloned AMV First-Strand cDNA synthesis kits (Invitrogen, Carlsbad,
CA) were used to prepare cDNA. SYBR green-based real-time PCR
was performed to determine the mRNA levels of LIN-28B and IGF-II.
The qPCR was carried out as described elsewhere [5,16], including
information on primer sequences. Briefly, in a volume of 20 μl PCR re-
action, 1 μl of cDNA template was mixed with 10 μl of 2× Power
SYBR® PCR master mix (Applied Biosystems, Foster City, CA),
200 nM of paired primers of either target genes of LIN-28B or IGF-II
or internal controls of RNU48 and GAPDH, and distilled water. The
PCR amplification included initial incubation at 50 °C for 2min, dena-
turing at 95 °C for 10min, and 40 cycles of denaturing at 95 °C for 15 s
and annealing at 60 °C for 1 min. Melting curves were analyzed after
each run to verify the size of the PCR products.
The miRNA cDNAs were prepared using TaqMan® microRNA Re-
verse Transcription kits (Applied Biosystems) as described elsewhere
[7]. Analysis of let-7a expression in tumor tissue was performed using
TaqMan® microRNA assay (Applied Biosystems) following the
manufacturer's instructions. Briefly, levels of let-7a and RNU48 (an
Table 1
Clinical and pathologic characteristics of patients.
Variables N %
Age (years), Mean (range) 208 57.9 (26–82)
Tumor Grade 211
1 34 16.1
2 40 19.0
3 137 64.9
Disease stage 211
I 52 24.6
II 12 5.7
III 133 63.0
IV 14 6.6
Residual tumor size (cm) 207
0 91 44.0
N0 116 56.0
Histological type 211
Serous Papillary 85 40.3
Endometrioid 41 19.4
Undifferentiated 36 17.1
Mucinous 18 8.5
Clear Cell 16 7.6
Müllerian 14 6.6
Other 1 0.5
Debulking results 208
Optimal 108 51.9
Suboptimal 100 48.1
Chemotherapy response 176
No 48 27.3
Yes 128 72.7
Gene expression N Median (5th–95th range)
LIN-28B 211 0.01 (0–6.00)
Let-7a 211 4.63 (0.53–35.3)
IGF-II 202 11.07 (0–3834)
Fig. 1. Classification and Regression Tree (CART) analysis of the LIN-28B/let-7a/IGF-II axis.
The cutoff values for LIN-28B, let-7a and IGF-II expression levels were determined by an
unsupervised algorithm for the maximization of the hazard ratio differentiating
survivors from non-survivors as described in the Materials and Methods. The terminal
branches were named as subtypes. ‘n’ is the number of patients in a particular branch.
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termined with the TaqMan® miRNA assay (Applied Biosystems). In
the PCR reaction (15 μl), 0.3 μl of cDNA template was mixed with
7.5 μl of 2X TaqMan® Universal PCR master mix (Applied Biosystems),
0.75 μl of 20X probe/primers (Applied Biosystems) of either let-7a or
RNU48, and water. The PCR amplification conditions were the same as
the quantification of LIN-28B and IGF-II in this study.
All qPCR assayswere completed using the Chromo4™ Real-time PCR
System (MJ Research Inc., Waltham, MA). Each sample was analyzed in
duplicate, and the analysis was repeated for those with CV above 5%.
2.3. Statistical analysis
Expressions of LIN-28B, let-7a and IGF-IIwere quantified bymeans of
expression index (EI), which was calculated based on the formula
1000×2 (−ΔCt), whereΔCt=Cttarget gene− Ctinternal control. Classification
and Regression Tree (CART) was constructed in each branch using the
optimal cutoff values of LIN-28B, let-7a and IGF-II expressions, a point
best distinguishing survivors and non-survivors, whichwas determined
by an unsupervised algorithmof themaximization of hazard ratio as de-
scribed elsewhere [29]. Associations between clinicopathologic features
and the CART subtypes were analyzed using the Chi-square statistic or
general linear model. Unconditional logistic regression analyses were
performed to estimate odds ratios (ORs) and their corresponding 95%
confidence intervals (95% CIs) for the associations of LIN-28B/let-7a/
IGF-II axis expression and clinicopathologic variables. Cox proportional
hazards regression survival analyses were also conducted to assess the
associations of the subtypes with risks of disease progression and mor-
tality. The survival times for overall and disease progression-free surviv-
alwere calculated as time from surgery until death or relapse, or the last
follow-up, respectively. All statistical analyses were carried out using
SAS version 9.3. A two-tailed p value less than 0.05 was considered sta-
tistically significant, and the results were highlighted in bold in tables.
3. Results
3.1. Clinical and pathologic characteristics of patients
Table 1 shows the clinical and pathologic features of patients. Patient
age at surgery was 57.9 years on average (range: 26–82). The majority
of patients had a disease with advanced stage and poor differentiation.
3.2. LIN-28B, let-7a and IGF-II expressions and CART analysis in epithelial
ovarian cancer
Due to the limited tumor tissue samples, only 202 samples provided
sufficient RNAs for IGF-II assay. The average EIs of LIN-28B, let-7a and
IGF-II expression levels were 0.01 (5th – 95th percentile range: 0–6.0),
4.63 (range: 0.53–35.3) and 11.07 (range: 0–3834), respectively
(Table 1). In our previous studies, we reported high levels of LIN-28B
and IGF-II expression associatedwith increased risk of relapse and over-
all mortality [5,16], and high let-7awas related to these increased risks
in patients receiving platinum and paclitaxel treatment. However, an
opposite effect of high let-7a on survival outcomes was observed in pa-
tients treated with platinum without paclitaxel [30]. To investigate the
effects of gene–gene interaction on patient survival, we performed
CART analysis. Fig. 1 shows the results of CART analysis focusing on
LIN-28B/let-7a/IGF-II expressions. A total number of 197 patients had
full data available for both gene expressions and vital status. Of 197 pa-
tients, 91 died of the disease, and 93 had recurrence. Using an unsuper-
vised algorithm of the maximization of the hazard ratio for overall
mortality, the optimal cutoff values for LIN-28B, let-7a and IGF-II were
determined. The cutoff value for LIN-28Bwas 0.125 EI which classified
patients into two groups, one (named terminal subtype #1) containing
72 patients with LIN-28B ≥ 0.125 EI (LIN-28Bhigh), and the other 125 pa-
tients with LIN-28B b 0.125 EI (LIN-28Blow). Further classification of thelatter groupwith a cutoff value of let-7a at 1.32 EI, 22 of the 125 patients
with let-7a b 1.32 EI (let-7alow) were grouped into terminal subtype #2
(LIN-28Blowlet-7alow), and 103 patients with let-7a ≥ 1.32 EI (let-7ahigh)
in another group which was further divided by IGF-II levels. The IGF-II
cutoff value was 6.85 EI, which classified the patients with low LIN-
28B (b0.125 EI) but high let-7a (≥ 1.32 EI) into two subtypes, subtype
#3 (LIN-28Blowlet-7ahigh IGF-IIlow) having 56 patients with IGF-II b 6.85
EI (IGF-IIlow), and subtype #4 (LIN-28Blowlet-7high IGF-IIhigh), with 47 pa-
tients with IGF-II ≥ 6.85 EI (IGF-IIhigh). No further classification of the
subtype #1 was based on the evidence that high LIN-28B, a cancer
stem cell-associated gene, was associated with poor prognosis of
human cancer such as ovary and liver [1,5,6]. In addition, no significant
differences in disease survival were observed across the subgroups
whenwe used the same approach to classifying the subtype #1 into dif-
ferent subgroups (data not shown).
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clincopathologic features of epithelial ovarian cancer
We first evaluated the associations of the LIN-28B/let-7a/IGF-II axis
molecular subtypes with clinicopathologic features of 197 patients
with both gene expressions and vital status; the results are shown in
Table 2. Borderline significant difference in patient agewas found across
the subtypes (p = 0.050), and patients with the subtype #3 showed
younger. We found significant associations of the axis with disease
stage (p = 0.037), residual tumor size (p = 0.001) and debulking re-
sults (p = 0.001), and no significant associations with tumor grade
(p = 0.112), chemotherapy response (p = 0.064), and histological
type (p = 0.074). To assess the strength of associations between the
CART subtypes and clinicopathologic features, we performed uncondi-
tional logistical regression analyses with the adjustment for patient
age at surgery. Across all the features analyzed, no statistically signifi-
cant differences were found between subtype #4 and #1. However, pa-
tients in subtypes #2 and #3 were less likely to have larger residual
tumors or suboptimal debulking results compared to those in subtype
#1. The adjusted odds ratios (ORs) for subtype #2 patients were 0.17
(95% CI: 0.06–0.49) and0.15 (95%CI: 0.05–0.49), and for subtype #3 pa-
tients were 0.35 (95% CI: 0.17–0.75) and 0. 44 (95% CI: 0.21–0.90) with
regard to having larger residual tumors or suboptimal debulking results,
respectively. We also found that patients in subtype #2 were less likely
to have advanced disease stage or high tumor grade andmore like to re-
spond to chemotherapy compared to those in subtype #1; their adjust-
ed ORswere 0.27 (95% CI: 0.10–0.73), 0.34 (95% CI: 0.13–0.92), and 8.77
(95% CI: 1.09–70.4), respectively. In addition, patients in subtype #3
were less likely to have serous tumors or type II (based on theTable 2
Associations of the LIN-28B/let-7a/IGF-II axis molecular subtypes with clinicopathologic feature
Variable N Subtype1 #1
n (%)
Subtype
n (%)
Age2 (mean ± SD, years) (n) 197 59.2 ± 11.3 (72) 61.5 ±
Disease stage 197
I–II 56 15 (26.8) 11 (19.6
III–IV 141 57 (40.4) 11 (7.8)
OR3 (95% CI4) Reference 0.27 (0.
Tumor grade 197
1 67 19 (28.4) 11 (16.4
2–3 130 53 (40.8) 11 (8.5)
OR (95% CI) Reference 0.34 (0.
Residual tumor size (cm) 197
0 83 22 (26.5) 16 (19.3
N0 114 50 (43.9) 6 (5.3)
OR (95% CI) Reference 0.17 (0.
Histological type 197
Non-serous 117 35 (29.9) 13 (11.1
Serous 80 37 (46.3) 9 (11.3)
OR (95% CI) Reference 0.65 (0.
Histological type5 197
Type I 48 9 (18.8) 7 (14.6)
Type II 149 63 (42.3) 16 (10.7
OR (95% CI) Reference 0.33 (0.
Debulking results 197
Optimal 99 29 (29.3) 18 (18.2
Suboptimal 98 43 (43.9) 4 (4.1)
OR (95% CI) Reference 0.15 (0.
Chemotherapy response 173
No 47 21 (44.7) 1 (2.1)
Yes 126 42 (33.3) 19 (14.3
OR (95% CI) Reference 8.77 (1.
Note: The results with p b 0.05 are highlighted in bold.
1 Subtype #1: LIN-28Bhigh; subtype #2: LIN-28Blowlet-7alow; subtype #3: LIN-28Blowlet-7ahigh
2 SD: standard deviation.
3 OR: odds ratio obtained from the unconditional logistical regression model adjusted with p
disease stage) as the event in the dependent variable.
4 CI: confidence interval.
5 Classification of type I and II tumors [31]: type I includes low-grade (grade 1) serous, low-gr
2 and 3) serous, high-grade endometrioid, undifferentiated carcinoma and malignant mixed mclassification defined by Kurman and colleagues [31]) compared to
those in subtype #1. The adjusted ORs were 0.38 (95% CI: 0.18–0.81),
and 0.26 (95% CI: 0.11–0.65), respectively.
3.4. Associations of LIN-28B/let-7a/IGF-II axis molecular subtypes with
patient survival
Kaplan–Meier survival curves according to the LIN-28B/let-7a/IGF-II
axis subtypes were constructed for overall and for disease progression
free survival. Figs. 2 and 3 show that both subtypes #2 and #3 had sig-
nificantly better overall and disease progression free survival than sub-
types #1 and #4 (p b 0.0001 and p= 0.017, respectively). The overall
survival curves did not differ significantly between subtypes #2 and
#3; neither did those differ between subtypes #1 and #4. The disease
progression free survival curves were also not separable between sub-
types #2 and #3 until the end of 60-month follow-up, and for subtypes
#1 and #4 the curves were not distinct throughout the follow-up. The
associations remained significant when only the patients receiving che-
motherapy were included in Kaplan–Meier survival curve analyses
(p= 0.0001 for overall survival, and p= 0.040 for disease progression
free survival) (supplementary Figs. 1 and 2).
To confirm the results of Kaplan–Meier survival analysis and to
adjust for potential confounding factors, we further analyzed the
data with multivariate Cox proportional hazards regression models.
The results of the multivariate analyses are shown in Table 3. Com-
pared to subtype #1, subtypes #2 (p = 0.038) and #3 (p b 0.0001)
but not subtype #4 (p=0.144) had significantly decreasedmortality
risks with adjustment for patient age at surgery, disease stage, tumor
grade, residual tumor size, histological type and chemotherapys.
#2 Subtype #3
n (%)
Subtype #4
n (%)
p value
8.5 (22) 54.8 ± 11.2 (56) 58.8 ± 11.5 (47) 0.050
0.037
) 19 (33.9) 11 (19.6)
37 (26.2) 36 (25.5)
10–0.73) 0.50 (0.23–1.13) 0.86 (0.36–2.08)
0.112
) 23 (34.3) 14 (20.9)
33 (25.4) 33 (25.4)
13–0.92) 0.55 (0.26–1.18) 0.85 (0.38–21.93)
0.001
) 30 (36.1) 15 (18.1)
26 (22.8) 32 (28.1)
06–0.49) 0.35 (0.17–0.75) 0.93 (0.42–2.06)
0.074
) 40 (34.2) 29 (24.8)
16 (20.0) 18 (22.5)
25–1.74) 0.38 (0.18–0.81) 0.59 (0.28–1.24)
0.014
20 (41.7) 12 (25.0)
) 36 (24.2) 34 (22.8)
10–1.00) 0.26 (0.11–0.65) 0.40 (0.16–1.06)
0.001
) 34 (34.3) 18 (18.2)
22 (22.5) 29 (29.6)
05–0.49) 0.44 (0.21 – 0.90) 1.09 (0.51 – 2.31)
0.064
12 (25.5) 13 (27.7)
) 36 (28.6) 29 (23.8)
09–70.4) 1.63 (0.70–3.83) 1.17 (0.51–2.72)
IGF-IIlow; subtype #4: LIN-28Blowlet-7ahigh IGF-IIhigh.
atient age at surgery, in which the second level of the variable (e.g., III-IV in the variable of
ade endometrioid, clear cell, mucinous and Brenner; and type II includes high-grade (grade
esodermal (or Müllerian) tumors.
Fig. 2. Kaplan–Meier overall survival curves of epithelial ovarian cancer stratified by the
molecular subtypes of the LIN-28B/let-7a/IGF-II axis. The curves for the subtypes #2
(LIN-28Blowlet-7alow) and #3 (LIN-28Blowlet-7ahigh IGF-IIlow) could not be separated,
neither could curves for the subtypes #1 (LIN-28Bhigh) and #4 (LIN-28Blowlet-7ahigh IGF-
IIhigh). Patients in subtypes #2 and #3 had better overall survival than those in the
subtypes #1 and #4 (p b 0.0001, log-rank test).
Table 3
Associations of LIN-28B/let-7a/IGF-II axis molecular subtypes and patient survival of epi-
thelial ovarian cancer.
Variable Death Relapse
HR1 95% CI 2 p value HR 95% CI p
value
Group3
Subtype #1 1.00 1.00
Subtype #2 0.36 0.14–0.94 0.038 0.44 0.19–0.99 0.047
Subtype #3 0.31 0.17–0.56 b0.0001 0.56 0.33–0.96 0.035
Subtype #4 0.68 0.41–1.14 0.144 0.86 0.51–1.45 0.563
Age 1.00 0.98–1.02 0.847 1.01 0.99–1.03 0.484
Disease stage 1.53 1.05–2.21 0.026 1.44 1.03–2.02 0.032
Tumor grade 1.55 1.00–2.41 0.050 1.27 0.87–1.84 0.209
Residual tumor size 1.26 1.16–1.37 b0.0001 1.11 1.02–1.20 0.012
Histological type
(Serous vs non-serous)
0.801 0.52–1.27 0.362 1.37 0.88–2.15 0.166
Chemotherapy (Yes vs
No)
0.45 0.19–1.04 0.061 1.69 0.51–5.57 0.388
Note: The results with p b 0.05 are highlighted in bold.
1 HR: hazard ratio obtained from a multivariate Cox proportional hazard regression
analysis, inwhichpatient age, disease stage, tumor grade and residual tumor size are treat-
ed as numerical variables, while the group of the subtypes (#2, #3, #4 vs #1, respectively)
obtained from the CART analysis, histological type (serous vs. non-serous) and chemo-
therapy status (yes vs no) are treated as categorical variables.
2 CI: confidence interval.
3 Subtype #1: LIN-28Bhigh; subtype #2: LIN-28Blowlet-7alow; subtype #3: LIN-28Blowlet-
7ahigh IGF-IIlow; subtype #4: LIN-28Blowlet-7ahigh IGF-IIhigh.
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0.14–0.94) for subtype #2, 0.31 (95% CI: 0.17–0.56) for subtype #3,
and 0.68 (95% CI: 0.41–1.14) for subtype #4. Compared to subtype
#1, subtypes #2 and #3 but not #4 had significantly reduced risks of re-
lapse. The adjusted HRs for relapse were 0.44 (95% CI: 0.19–0.99) for
subtype #2 (p = 0.047), 0.56 (95% CI: 0.33–0.96) for subtype #3
(p= 0.035), and 0.86 (95% CI: 0.51–1.45) for subtype #4 (p= 0.563).4. Discussion
In this study, we demonstrated the associations of the LIN-28B/let-
7a/IGF-II axis molecular subtype with patient survival in epithelial
ovarian cancer. Patients with either LIN-28Bhigh or LIN-28B low let-7a high
IGF-II high had aggressive disease and unfavorable survival compared to
patients with either LIN-28B low let-7a low or LIN-28Blowlet-7ahigh IGF-
IIlow. Moreover, patients in subtype #2 who had the subtype of LIN-28BFig. 3. Kaplan–Meier disease progression free survival curves of epithelial ovarian cancer
stratified by the molecular subtypes of the LIN-28B/let-7a/IGF-II axis. The curves for the
subtypes #2 (LIN-28Blowlet-7alow) and #3 (LIN-28Blowlet-7ahigh IGF-IIlow) could not be
separated, neither could curves for the subtypes #1 (LIN-28Bhigh) and #4 (LIN-28Blowlet-
7ahigh IGF-IIhigh). Patients in subtypes #2 and #3 had better disease progress free survival
than those in the subtypes #1 and #4 (p= 0.028, log-rank test).low let-7a low had better response to chemotherapy that are effective in
eliminating rapidly proliferating cancer cells. As shown in the results, pa-
tients in the subtype #1 (LIN-28Bhigh) had higher cancer stem cell-
associated gene LIN-28B expression, and in the subtype #4 (LIN-28B low
let-7a high IGF-II high) had particularly higher expression of IGF-II, a stem
cell and cancer development-associated signaling, in comparison with
the subtypes #2 and #3. These results suggest that different molecular
mechanisms are underlying the progression of epithelial ovarian cancer
in term of LIN-28B/let-7a/IGF-II axis.
LIN-28B has been suggested to be an oncogene [2,11], and its
encoded protein is a transcription factor involved in maintaining prop-
erties of cancer stem cells [32], the culprit of the aggressiveness andme-
tastasis of disease, and resistance to therapy. Hosonuma and colleagues
[33] showed that ovarian cancer patients with stem cell-like side popu-
lations of tumor cells had worse prognoses than those without. In vitro
and in vivo experiments show that progenitor-like cells make the be-
havior of human epithelial ovarian cancer aggressive [34]. Similarly,
King and colleagues [35] showed that the activation of LIN-28B stimulat-
ed the expression of the intestinal/colonic epithelial stem cell markers
LGR5 and PROM1, and promoted the migration, invasion and transfor-
mation of immortalized colonic epithelial cells. Another previous
study also showed that down-regulation of LIN-28B could repress the
self-renewal capability of prostate cancer cell lines [32]. Animal models
indicate that LIN-28B activation promotes cancer growth; LIN-28B si-
lencing significantly inhibits MYC-dependent cell proliferation [36]. In
agreement with our present results, the association of high LIN-28B ex-
pression with poor clinical outcome has also been observed in other
human cancers, including esophagus, and head and neck [22,37]. More-
over, in line with our findings that subtype #1 with high LIN-28B ex-
pression had unfavorable clinical features of epithelial ovarian cancer,
it has been reported that aberrant up-regulated LIN-28B expression is
observed in subsets of tumors that are poorly differentiated [6,35].
Interestingly, we also found that subtype #4, one of the branches
with the subtype of LIN-28B low let-7a high IGF-II high, had worse survival
than subtype #3 of the LIN-28B low let-7a high IGF-II low. Moreover,
although patients with low LIN-28B expression may have favorable
prognosis compared to those with the high one, if patients also had
high let-7a particularly high IGF-II expression, they also showed an infe-
rior prognosis. This result indicates that IGF-II is an unfavorable marker
in ovarian cancer prognosis as we previously reported [16], and also is
126 L. Lu et al. / Gynecologic Oncology 141 (2016) 121–127consistent with other studies. Huang et al. [38] showed ovarian cancer
patients with high IGF-II had shorter survival and unfavorable disease,
as well as paclitaxel resistance. This group recently reported that IGF-II
silencing could make drug resistant-ovarian cancer responsive to
paclitaxel [39]. Slipicevic and colleagues analyzed IGF-II levels in
post-chemotherapy ovarian cancer effusions, and found a negative
association between IGF-II levels and patient survival [40]. An in vitro
study revealed that human monoclonal antibodies against IGF-IR
could suppress IGF-II-dependent ovarian cancer growth, and increase
sensitivity to cisplatin in ovarian cancer xenograft models [18].
MicroRNA let-7a is one member of the let-7 family, which is well-
characterized in fine-tuning gene expression, and plays important
roles in cell proliferation, differentiation, apoptosis and metabolism
[24]. Aberrant expression of let-7a has been reported in various types
of human cancer [41], and is associated with cell proliferation, chemo-
therapy response, and patient survival [30,42]. Evidence suggests that
let-7a may operate in favor of tumor progression in human tumors
under certain conditions [7,30]. In the present study, we found that sub-
type #3 (LIN-28Blowlet-7ahigh IGF-IIlow), despite high let-7a, had relative-
ly better survival compared to subtype #4 (LIN-28Blowlet-7ahighIGF-
IIhigh), which was also from the branch of high let-7a expression. This
finding suggests that let-7amay play different roles in the prognosis of
these two groups with different levels of IGF-II expression. In addition,
it was recently reported that down-regulation of let-7a in the LIN-28B/
let-7a signaling could sensitize ovarian cancer response to chemothera-
py [43]. This observation is in agreementwith our finding of chemother-
apy response in subtype #2 patients. Taken together, the findings in our
study suggest that LIN-28B, let-7a and IGF-II interplay with each other,
forming a complicated axis. Thus, it may not be unexpected that pa-
tients with the molecular subtypes in different combinations of the
axis had their distinct outcomes.
In summary, we have shown that patients with the signatures of
either LIN-28Bhigh or LIN-28Blowlet-7ahighIGF-IIhigh had worse progno-
ses and unfavorable disease in comparison to those with either the
LIN-28Blowlet-7alow or the LIN-28Blowlet-7ahigh IGF-IIlow in epithelial
ovarian cancer. The results show that different molecular subtypes
of the LIN-28B/let-7a/IGF-II axis have distinct progression courses,
suggesting that the classification of the LIN-28B/let-7a/IGF-II axis
subtypes may help to select patients in clinical trials to explore sys-
temic or targeted therapies that can prevent or delay relapse and im-
prove survival, and that the axis may have potential in designing
precision medications for epithelial ovarian cancer. For example, pa-
tients with the signature LIN-28Blowlet-7ahighIGF-IIhigh should be
treated as aggressively as those with LIN-28Bhigh, but different tar-
gets should be relevant for these two subgroups in designing target
therapies. Similarly, individualized target therapy strategies may be
necessary for patients with LIN-28Blowlet-7alow or LIN-28Blowlet-
7ahigh IGF-IIlow, although their prognoses are similar.
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